Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 11:27 AM ET

Pharmaceuticals

Company Overview of Alcobra Ltd.

Company Overview

Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and in Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.

Amot Investment Building

9th Floor

2 Weizman Street

Tel Aviv,  6423902

Israel

Founded in 2008

13 Employees

Phone:

972 72 220 4661

Key Executives for Alcobra Ltd.

Alcobra Ltd. does not have any Key Executives recorded.

Alcobra Ltd. Key Developments

Alcobra Ltd. Reporta Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Alcobra Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss attributable to holders of ordinary shares of $5,123,000 or $0.24 per basic and diluted per share against $7,780,000 or $0.57 per basic and diluted per share a year ago. Loss before taxes on income was $5,109,000 against $7,774,000 reported last year. Net cash used in operating activities was $3,891,000 against $5,468,000 a year ago. Purchase of property and equipment was $24,000 against $20,000 last year. For the six months, the company reported net loss attributable to holders of ordinary shares of $10,300,000 or $0.50 per basic and diluted per share against $15,546,000 or $1.14 per basic and diluted per share a year ago. Loss before taxes on income was at $10,273,000 against $15,531,000 reported last year. Net cash used in operating activities was $8,486,000 against $11,096,000 a year ago. Purchase of property and equipment was $36,000 against $70,000 last year.

Alcobra Ltd. to Report Q2, 2015 Results on Aug 13, 2015

Alcobra Ltd. announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Aug 13, 2015

Alcobra Ltd., Q2 2015 Earnings Call, Aug 13, 2015

Alcobra Ltd., Q2 2015 Earnings Call, Aug 13, 2015

Similar Private Companies By Industry

Company Name Region
SimeTRA Pharm Ltd. Middle East/Africa
Perrigo Israel Pharmaceuticals Limited Middle East/Africa
Topimed Ltd. Middle East/Africa
ConjuGate Ltd. Middle East/Africa
Sol-Gel Technologies Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alcobra Ltd., please visit www.alcobra-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.